Clinical Trial Update: Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating LN-145/LN-145-S1 autologous tumor infiltrating lymphocytes for squamous cell carcinoma of the head and neck has completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• LN-145 (autologous tumor-infiltrating lymphocytes)
• LN-145-S1

Snippet

Sponsor: Iovance Biotherapeutics, Inc. | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2023-10-12